• *Decision marks win for International Stem Cell Corp. BRUSSELS/ LONDON, Dec 18- Europe's top court has opened the door to certain stem cell patents in the European Union by ruling that an organism incapable of developing into a human being is not a human embryo and may be patented. Thursday's judgment by the European Court of Justice was made following a case...

  • Celgene CEO: Cancer drug pipeline booming   Monday, 8 Dec 2014 | 12:37 PM ET
    Celgene CEO: Cancer drug pipeline booming

    CNBC's Meg Tirrell speaks to Robert Hugin, Celgene chairman & CEO, about exciting new drugs emerging from Celgene's pipeline and the progress being made with Multiple myeloma.

  • Two biotechs to track now   Friday, 5 Dec 2014 | 5:23 PM ET
    Two biotechs to track now

    Two stocks you need to watch ahead of San Francisco's 56th ASH hematology conference, with CNBC's Meg Tirrell.

  • RBC's biotech picks: CELG, BMRN & VRTX   Tuesday, 2 Dec 2014 | 5:18 PM ET
    RBC's biotech picks: CELG, BMRN & VRTX

    Discussing some of the best stocks in the biotech industry going into 2015, with Michael Yee, RBC Capital Markets.

  • Biogen shows its hand   Tuesday, 2 Dec 2014 | 5:15 PM ET
    Biogen shows its hand

    CNBC's Meg Tirrell provides insight to Biogen Idec's promising early study on its experimental medicine for Alzheimer's disease. Michael Yee, RBC Capital Markets, explains why the stock is headed higher from here.

  • Biogen's fight against Alzheimer's   Tuesday, 2 Dec 2014 | 2:19 PM ET
    Biogen's fight against Alzheimer's

    Biogen's Alzheimer's drug has shown promise in studies, with CNBC's Meg Tirrell.

  • Banned in US, cleared in the UK   Monday, 1 Dec 2014 | 7:00 PM ET
    Banned in US, DNA testing service reaches UK

    A Google-backed service to map DNA and identify potential risk factors for some diseases has been launched in the U.K., months after it was banned in the U.S..

  • Tracking the Allergan-Actavis merger   Monday, 17 Nov 2014 | 7:32 PM ET
    Tracking the Allergan-Actavis merger

    Sachin Shah, Analyst at Albert Fried and Company, discusses news that botox maker Allergan agreed to a $66 billion takeover bid from Actavis.

  • Geron sells last drug in pipeline to J&J unit Thursday, 13 Nov 2014 | 6:27 PM ET

    Nov 13- Geron Corp licensed its cancer compound, the last in its pipeline, to a unit of Johnson& Johnson for up to $935 million, sending its shares up as much as 33 percent in extended trading. The license deal comes as a welcome break to the company, which has seen its stock price drop from a high of $71.69 in 2000 to $2.31 on Thursday. If successful, imetelstat would...

  • Dendreon files bankruptcy protection   Monday, 10 Nov 2014 | 10:38 AM ET
    Dendreon files bankruptcy protection

    Prostate cancer drug developer Dendreon has filed for Chapter 11 bankruptcy protection. CNBC's Meg Tirrell takes a close look at what contributed to the company's downfall.

  • Integrating vets into corporate America: J&J CEO   Wednesday, 5 Nov 2014 | 2:30 PM ET
    Integrating vets into corporate America: J&J CEO

    CNBC's Meg Tirrell speaks to Alex Gorsky, Johnson & Johnson chairman & CEO, about helping military veterans transition from the battlefield into corporate America.

  • Arena Pharma's 'Belviq' potential   Monday, 3 Nov 2014 | 2:40 PM ET
    Arena Pharma's 'Belviq' potential

    Jack Lief, Arena Pharmaceutical president & CEO, breaks down the company's Q3 earnings and discusses the outlook for its weight loss drug "Belviq."

  • Russia comes to Silicon Valley to recruit Monday, 3 Nov 2014 | 10:52 AM ET
    The Skolkovo Hypercube  in Moscow, Russia.

    Russia has a new tech city chock-full of co-working spaces, seed funding, and a research university. All they need now are the technologists.

  • Bull case for biotech   Monday, 27 Oct 2014 | 11:25 AM ET
    Bull case for biotech

    CNBC's Bertha Coombs takes a close look at the wild swings taking place in the biotech sector.

  • Run up in biotech is highly rational: UBS   Wednesday, 22 Oct 2014 | 5:35 AM ET
    Run up in biotech is highly rational: UBS

    Matthew Roden, executive director of biotechnology equity research at UBS argued biotech stock valuations are still attractively valued even after their run higher.

  • Ebola stocks: Who's leading?   Wednesday, 1 Oct 2014 | 2:21 PM ET
    Ebola stocks: Who's leading?

    Discussing which biotech companies working on treatments for deadly viruses are the most investable, with Dr. Neil Shahrestani, Pura Vida analyst.

  • GMO 'superseeds' leading to 'superweeds' Tuesday, 30 Sep 2014 | 11:22 AM ET
    Irrigation on corn field

    The newest batch of crop seeds is setting off another debate over GMOs. This time, they're being blamed for an infestation of "superweeds."

  • Cramer: Stay on biotech   Wednesday, 24 Sep 2014 | 8:51 AM ET
    Cramer: Stay on biotech

    CNBC's Jim Cramer takes a look at what's putting pressure on the markets and why he is watching the biotech sector.

  • ImClone's Waksal plans IPO   Wednesday, 24 Sep 2014 | 7:31 AM ET
    ImClone's Waksal plans IPO

    CNBC's Meg Tirrell reports Sam Waksal is back in the biotechnology industry.

  • Tax crackdown impact on pharma deals   Tuesday, 23 Sep 2014 | 2:45 PM ET
    Tax crackdown impact on pharma deals

    Discussing how the Treasury Department's new rules to end tax inversions could impact the pharma deals, with Michael Faerm, Wells Fargo Securities.